U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about 510 billion ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes and cancer with “precision medicine”. Leverage the power of TipRanks ...

TOKYO : Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion ...

BOSTON & BATESVILLE, Ind.--(BUSINESS WIRE)--Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the ...